Patrick A Ott Selected Research

Radiotherapy

1/2021	NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021.
12/2020	Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial.
1/2019	Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.
1/2019	Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy.
1/2019	The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors.
1/2016	Talimogene Laherparepvec for the Treatment of Advanced Melanoma.
11/2015	A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab.
7/2013	Vemurafenib and radiation therapy in melanoma brain metastases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Patrick A Ott Research Topics

Disease

88	Melanoma (Melanoma, Malignant) 04/2024 - 01/2009
88	Neoplasms (Cancer) 04/2024 - 01/2010
13	Disease Progression 01/2022 - 05/2015
11	Neoplasm Metastasis (Metastasis) 01/2023 - 01/2011
8	Brain Neoplasms (Brain Tumor) 01/2022 - 01/2009
8	Renal Cell Carcinoma (Grawitz Tumor) 01/2019 - 03/2013
7	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2024 - 02/2015
7	Colitis 01/2021 - 11/2016
5	Pneumonia (Pneumonitis) 08/2021 - 07/2016
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 06/2017
4	Stomach Neoplasms (Stomach Cancer) 01/2021 - 01/2020
4	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 04/2005 - 09/2002
3	COVID-19 04/2024 - 05/2021
3	Fatigue 03/2024 - 01/2009
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2020 - 07/2016
3	Uveal melanoma 12/2018 - 10/2013
3	Hematologic Neoplasms (Hematological Malignancy) 01/2017 - 01/2016
3	Exanthema (Rash) 01/2017 - 01/2009
2	Dermatitis 03/2024 - 08/2021
2	Squamous Cell Carcinoma of Head and Neck 03/2024 - 10/2022
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 10/2022 - 12/2017
2	Lung Neoplasms (Lung Cancer) 01/2022 - 12/2016
2	Inflammation (Inflammations) 01/2019 - 03/2013
2	Carcinoma (Carcinomatosis) 01/2019 - 11/2016
2	Endometrial Neoplasms (Endometrial Cancer) 12/2017 - 08/2017
2	Hypothyroidism 12/2017 - 01/2017
2	Hypophysitis 11/2016 - 02/2015
2	Renal Insufficiency (Renal Failure) 07/2016 - 01/2013
2	Testicular Neoplasms (Testicular Cancer) 03/2015 - 06/2013
2	Infections 03/2013 - 02/2004
2	Thrombocytopenia (Thrombopenia) 01/2013 - 01/2009
2	Neutropenia 01/2013 - 01/2009
2	Chronic Disease (Chronic Diseases) 02/2004 - 09/2002
1	Colorectal Neoplasms (Colorectal Cancer) 03/2024
1	Skin Neoplasms (Skin Cancer) 01/2024

Drug/Important Bio-Agent (IBA)

57	Immune Checkpoint InhibitorsIBA 03/2024 - 06/2013
27	IpilimumabIBA 01/2024 - 06/2013
22	pembrolizumabIBA 01/2024 - 02/2015
18	NivolumabIBA 04/2024 - 02/2015
17	VaccinesIBA 04/2024 - 06/2014
16	Monoclonal AntibodiesIBA 03/2024 - 03/2013
14	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 06/2023 - 02/2013
10	AntigensIBA 01/2023 - 02/2004
9	B7-H1 AntigenIBA 11/2022 - 08/2017
8	Biomarkers (Surrogate Marker)IBA 04/2024 - 10/2013
8	Proteins (Proteins, Gene)FDA Link 11/2021 - 02/2004
8	LigandsIBA 01/2020 - 03/2013
7	CytokinesIBA 11/2021 - 09/2002
6	Cancer VaccinesIBA 04/2024 - 01/2018
6	Adrenal Cortex Hormones (Corticosteroids)IBA 08/2021 - 02/2015
5	EpitopesIBA 04/2024 - 07/2004
5	CTLA-4 AntigenIBA 10/2022 - 06/2013
5	Peptides (Polypeptides)IBA 01/2021 - 02/2004
5	AntibodiesIBA 01/2017 - 01/2014
4	trametinibIBA 06/2023 - 02/2013
4	VemurafenibIBA 01/2023 - 04/2013
3	dabrafenibIBA 06/2023 - 01/2014
3	Chimeric Antigen ReceptorsIBA 01/2023 - 01/2019
3	Neoplasm Antigens (Tumor Antigens)IBA 01/2019 - 06/2014
3	CreatinineIBA 01/2019 - 01/2013
3	EnzymesIBA 01/2015 - 02/2004
2	Protein Subunit VaccinesIBA 04/2024 - 01/2021
2	RNA (Ribonucleic Acid)IBA 04/2024 - 11/2018
2	tremelimumabIBA 02/2024 - 11/2021
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2024 - 01/2015
2	Imiquimod (Aldara)FDA LinkGeneric 01/2023 - 09/2022
2	Death Domain ReceptorsIBA 10/2022 - 11/2016
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022 - 01/2021
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 10/2021 - 01/2011
2	Programmed Cell Death 1 ReceptorIBA 01/2021 - 03/2013
2	Peptide Hydrolases (Proteases)FDA Link 01/2021 - 01/2021
2	ProdrugsIBA 01/2021 - 01/2021
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021 - 01/2017
2	Monatide (IMS 3015)IBA 01/2020 - 03/2015
2	glembatumumab vedotinIBA 01/2019 - 11/2014
2	Glycoproteins (Glycoprotein)IBA 01/2019 - 11/2014
2	Immunoconjugates (Immunoconjugate)IBA 01/2019 - 11/2014
2	Interleukin-10 (Interleukin 10)IBA 11/2018 - 10/2016
2	AutoantigensIBA 01/2018 - 07/2004
2	Phosphotransferases (Kinase)IBA 01/2017 - 10/2013
2	PlatinumIBA 11/2016 - 07/2016
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2016 - 09/2015
2	Cytotoxins (Cytolysins)IBA 11/2014 - 01/2011
2	Mitogen-Activated Protein KinasesIBA 01/2014 - 04/2013
2	Dacarbazine (DIC)FDA LinkGeneric 01/2013 - 01/2009
1	Anti-Bacterial Agents (Antibiotics)IBA 04/2024
1	Vancomycin FDA LinkGeneric 04/2024
1	Cetuximab (Erbitux)FDA Link 03/2024
1	urelumabIBA 03/2024
1	Prednisone (Sone)FDA LinkGeneric 01/2024
1	Tacrolimus (Prograf)FDA LinkGeneric 01/2024
1	prednylidene (Pred)IBA 01/2024
1	afliberceptIBA 01/2024
1	cobimetinibIBA 01/2023
1	LY3022855IBA 01/2023

Therapy/Procedure

64	Therapeutics 03/2024 - 06/2009
32	Immunotherapy 03/2024 - 02/2013
13	Drug Therapy (Chemotherapy) 01/2022 - 01/2009
8	Radiotherapy 01/2021 - 07/2013
4	Aftercare (After-Treatment) 01/2023 - 01/2017